By Adriano Marchese
Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the drug.
Shares fell 16% to $10.54.
The clinical-stage biopharmaceutical company said the decision was made after it observed pericardial effusion in patients, an adverse effect in which excess fluid builds up around the heart.
The company voluntarily halted all dosing in the phase 2 Tropos trial for the drug cibotercept, which aims to treat pulmonary arterial hypertension.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 15, 2025 09:54 ET (14:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.